Joining us this morning, Bank of America, head of US small and midcap strategy, Jill Kerry Hall is with us. Jill, good to have you back. >> Thanks.Good to be here. >> Especially on a day where the Russell does join the party uh not far away from 2500. I wonder if you think uh things are beginning to click for small caps that we really sort of wrestled with earlier in the year.>> Yeah, we've we've been constructive on small caps since um the end of August. And I think there's been three things that have kind ...

And welcome back to halftime. Let's get to some stocks on the move. Bergkshire to acquire Oxycm for $9.7% billion.This is the chemical business of Oxidental. $9.7% billion all cash deal. You're seeing Bergkshire pull back a little bit.Oxy pull back a lot, but you're a Bergkshire Hathaway shareholder. What do you make of this deal. >> Um, I think it's intriguing.I like it, but I have to put it in perspective that versus a 300 billion plus dollar uh cash pile, this is, you know, 3% of that pile is probably wh ...

Article content“Canadian equities remain well-positioned to keep pace with the U.S. … period,” BMO Capital Markets chief investment strategist Brian Belski said in a research paper updating the bank’s best investment ideas strategy. Canadian stocks are at the tail end of an earnings recovery that started in mid-2024, with profitability normalizing and growth now expected to reach double digits. “Despite narrowing valuation divergence of Canada versus the U.S., we continue to believe the Canadian small-cap u ...

Group 1 - Bank of America Securities has updated its outlook on UnitedHealth Group, maintaining a 'Neutral' rating while raising its price target to $325 from $290, reflecting a potential upside of nearly 7% from the current price of $304 [1] - The upward revision follows Berkshire Hathaway's recent $1.6 billion investment in UnitedHealth, which reaffirms market confidence in the healthcare giant [3] - Analysts see a potential earnings recovery in 2027, which could unlock additional upside for UnitedHealth [3] Group 2 - Despite the higher target, Bank of America remains cautious due to limited near-term earnings visibility and unresolved key uncertainties, which could lead to another 12 months of underperformance [4] - The company has faced leadership changes, suspended financial guidance, and federal probes into its Medicare Advantage billing practices, contributing to significant stock sell-offs [5] - UnitedHealth remains the largest Medicare Advantage provider with over 8 million members, while its Optum unit continues to expand in care and technology services [6]

Financial Data and Key Metrics Changes - The fourth quarter GAAP losses per common share were $1.90, while distributable earnings showed a loss of $0.03. Excluding realized losses on asset sales, distributable earnings were $0.23 per common share, representing a 7.1% return on average stockholders' equity [32] - Book value per share decreased to $10.61 from $12.59 in the previous quarter, primarily due to an increase in combined CECL and valuation allowance [40] Business Line Data and Key Metrics Changes - The core portfolio contracted by $1.3 billion, with new production limited to $485 million, resulting in an 840 basis points contribution to distributable ROE before realized losses [15] - Small business lending operations experienced significant origination growth of 1.7%, with fourth quarter originations of $350 million, capping a record year of $1.2 billion [22] Market Data and Key Metrics Changes - The CRE loan portfolio totaled $7.2 billion, split into 83% core and 17% non-core assets. The core portfolio has a contractual yield of 8% with a 93% pay rate [13] - 60-day plus delinquencies in the core portfolio were only 2%, with an average risk rating of 2.2% [14] Company Strategy and Development Direction - The company has undertaken aggressive actions to reset the balance sheet, including a $284 million combined CECL and valuation allowances, marking 100% of non-performing loans to current values [9] - The strategy involves bifurcating the CRE portfolio into core and non-core assets to enhance transparency and track asset management strategies [12] Management's Comments on Operating Environment and Future Outlook - Management expects recovery in net interest margin and ROE over the succeeding year, with a focus on aggressive liquidation of the non-core portfolio [10][29] - The company anticipates originating between $1 billion and $1.5 billion of new production in lower middle market CRE loans in 2025 [15] Other Important Information - The company has a strong liquidity position with $185 million of unrestricted cash and has raised $350 million of corporate financing across two transactions [41] - The company plans to execute a $150 million share repurchase program to enhance shareholder returns [11] Q&A Session Summary Question: Will cash earnings cover the new dividend level? - Management expects to cover the dividend approximately 1.5 times over the course of the year, with earnings ramping up as the year progresses [46] Question: What is the rationale behind the UDF acquisition? - The acquisition is viewed as highly accretive on an EPS basis, with a strong historical performance of the loans involved [78] Question: How does the company plan to address 2026 maturities? - The company plans to access markets for refinancing and has already started addressing some maturities with recent senior secured notes [72] Question: What are the credit trends in the SBA business? - The company has seen strong credit trends in its SBA portfolio, with 60-plus delinquencies remaining at a moderate level of 2.8% [89]